Jia YY, Wang J, Yang LM. Clinical significance of expression of USP22 and Nanog in colon cancer.
Shijie Huaren Xiaohua Zazhi 2013;
21:719-723. [DOI:
10.11569/wcjd.v21.i8.719]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the expression of USP22 and Nanog in colon cancer and to explore their relationship with clinicopathological factors of this malignancy.
METHODS: The expression of USP22 and Nanog was detected by immunohistochemistry in 80 cases of colonic adenocarcinoma, 35 cases of colonic adenoma and 40 cases of normal colonic tissue.
RESULTS: The positive rate of USP22 expression in colonic adenocarcinoma was significantly higher than those in colonic adenoma and normal tissues (both P < 0.05), but there was no significant difference between colonic adenoma and adenocarcinoma (P > 0.05). The positive rate of Nanog expression differed significantly in normal colonic tissue, colonic adenoma and colonic adenocarcinoma (all P < 0.05). The expression of USP22 and Nanog was correlated with Duke's stage, histopathological grade, lymph node metastasis and depth of invasion (all P < 0.05). There was a positive correlation between the expressions of USP22 and that of Nanog in colonic adenocarcinoma (r = 0.509, P < 0.01).
CONCLUSION: The expression of USP22 and Nanog is closely related to the occurrence and development of colonic adenocarcinoma, and they have synergistic effect on infiltration, invasion and metastasis of colonic adenocarcinoma. USP22 and Nanog may be used as early diagnostic markers and therapeutic targets for colorectal adenocarcinoma.
Collapse